Please assess the completion status of the following clinical trial:

Trial Title: Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes (WHO criteria)~* Diabetic nephropathy (2 out of 3 consecutive 24 hour urinary samples with albumin excretion \> 300 mg/24hour and diabetic retinopathy in the absence of signs of other kidney or urinary tract disease) 27 or diabetic glomerulosclerosis verified by biopsy.~* Hypertension: Blood pressure \> 135 mmHg systolic and/or 85 mm Hg diastolic repeatedly.~* Age from 18 to 70 years.~Exclusion Criteria:~* Age \< 18 years or \> 70 years.~* Pregnancy or fertile women not using adequate anticonceptive (intrauterine device, sterilization, or oral anticonceptive)~* Malignant hypertension.~* Blood pressure \> 180/105 mm Hg~* Known renal artery stenosis~* GFR \< 30 ml/min/1.73 m²~* Serum potassium \> 4.8 mmol/ l~* Heart failure, myocardial infarction, unstable angina or coronary bypass operation within the previous three months.~* Abuse of drugs or alcohol.~* Not able to understand the written information.~* Known intolerance to ACE inhibitors.~* Chronic use of non steroid inflammatory drugs or aspirin (above 1 g/day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).